4.2 Review

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence

期刊

EXPERT OPINION ON PHARMACOTHERAPY
卷 10, 期 14, 页码 2303-2315

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560903140533

关键词

adherence; bisphosphonates; compliance; fracture; osteoporosis; persistence

资金

  1. Bristol Myers Squibb
  2. Merck Sharpe and Dohme
  3. Rottapharm
  4. Teva
  5. Lilly
  6. Novartis
  7. Roche
  8. GlaxoSmithKline
  9. Amgen
  10. Servier

向作者/读者索取更多资源

Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic women are poor. Although extending dosing intervals improved adherence, the gains are suboptimal. Most importantly, low compliance and persistence rates consistently resulted in increased rates of fractures. The results emphasize the importance of adherence to treatment to achieve optimal antifracture efficacy. There is an urgent need to implement strategies and to encourage physicians to take measures that increase patients' awareness of the need to use osteoporosis medications as directed in order to benefit from them fully.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据